Search

A 4-year-old boy with microcytic anaemia and congenital sideroblastic anaemia did not show improvement with iron supplementation, pyridoxine, and folic acid. Despite these treatments, his anaemia persisted, indicating a lack of efficacy. The boy then received off-label treatment with luspatercept, which resulted in a significant improvement in his anaemia. This case highlights the potential benefits of luspatercept in managing anaemia in certain cases. [Extracted from the article]

A 38-year-old woman experienced severe toxic effects and acute liver failure after intentionally overdosing on ferrous-sulfate in a suicide attempt. She received various treatments, including charcoal, deferoxamine, flumazenil, acetylcysteine, and norepinephrine, but did not respond well to them. Eventually, she underwent a liver transplant and experienced clinical improvement. At the 6-month follow-up, she had no further complications. [Extracted from the article]

A 13-year-old boy developed slipped capital femoral epiphysis, nail discoloration, and nail brittleness while being treated with erdafitinib for optic pathway/hypothalamic glioma. He initially presented with emesis and headaches and was diagnosed with the glioma. After starting erdafitinib treatment, he experienced adverse reactions including nail discoloration and brittleness. He also developed hyperphosphatemia and intermittent pain in his right leg, which progressed to limping and difficulty walking. The boy was eventually diagnosed with slipped capital femoral epiphysis and underwent surgery. His tumor size decreased after the surgery and he remained stable. [Extracted from the article]

A 65-year-old woman with a history of transfusion-dependent myelodysplastic syndrome and neuroendocrine gastric tumor experienced a lack of efficacy during treatment with deferasirox as iron chelation therapy. Despite being on deferasirox, cardiac MRI indicated cardiac haemochromatosis. An endomyocardial biopsy revealed sarcoplasmic iron deposition with mild interstitial fibrosis. The woman's hospital stay was complicated by pericarditis, but she eventually received guideline-directed heart failure therapy and was discharged while continuing deferasirox treatment. [Extracted from the article]

A post hoc analysis of a clinical trial called the FIRST study found that three patients developed various toxicities after receiving deferiprone as iron chelation therapy. The toxicities included agranulocytosis, neutropenia, hepatic sequestration, hypersplenism, bacterial arthritis, and fulminant hepatitis. The study did not provide information about the patients' ages or genders, nor did it specify the dosages of deferiprone or the outcomes of the toxicities. [Extracted from the article]

A 25-year-old man developed mercury poisoning after receiving an injection of mercury for tinea cruris. He experienced symptoms such as fatigue, dry cough, and nausea. Physical examination revealed conjunctival pallor, and laboratory tests showed low hemoglobin levels and high levels of mercury in his blood and urine. Chest and abdominal radiographs showed metallic opacities in various organs. The man was treated with unithiol and chelation therapy, which improved his symptoms and reduced his mercury levels. [Extracted from the article]

IRON CHELATION THERAPY IN CONGENITAL HEMOLYTIC ANEMIAS: AN ITALIAN SINGLE CENTER STUDY. Due to anaphylactic shock, the patient's treatment with deferoxamine was switched to deferasirox [ I outcome not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective single centre study of 206 patients with documented history of iron chelation, a patient [ I age and sex not stated i ] was described, who developed non-fatal anaphylactic shock during iron chelation therapy with parenteral deferoxamine [ I dosage not stated i ] for congenital haemolytic anaemia [CHA; I duration of treatment to reaction onset not stated i ]. [Extracted from the article]

Subsequently, four days later, he was discharged from the hospital with an advice to maintain chelation therapy, chlordiazepoxide/clidinium bromide [Librax] and mebeverine. He had received treatment with scopolamine [hyoscine] and unspecified non-steroidal anti-inflammatory drugs [ I routes and dosages not stated i ] for abdominal pain with no effect. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 32-year-old man exhibited a lack of efficacy during treatment with hyoscine and unspecified non-steroidal anti-inflammatory drugs for abdominal pain. [Extracted from the article]

However, she subsequently developed mild infusion reactions, which she was unable to tolerate [ I time to reaction onset not clearly stated i ]. Thereafter, she was treated with immune globulin and iron chelation therapy, with prompt resolution of the anaemia and reticulocytopaenia, and normalisation of inflammatory markers [ I ADR outcome not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 65-year-old woman developed infusion reactions during treatment with rituximab for autoimmune dyserythropoiesis, and exhibited no response to the treatment. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study involving 60 patients (patients attended thalassemia daycare center between November 2013 and March 2015), a patient [ I age and sex not stated i ] was described, who exhibited ulnar shortening while receiving chelation therapy with deferiprone for thalassemia. The patient had transfusion-dependent thalassemia. Treatment with deferiprone was considered to be associated with the patient's ulnar shortening [ I duration of treatment to reaction onset and outcome not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 56-year-old man developed chronic obstipation during treatment with lanthanum carbonate as chelation therapy for phosphate binding. During anamnesis, he reported chronic obstipation since receiving lanthanum carbonate for phosphate binding [ I dosage, route and time to reaction onset not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 90-year-old man developed encephalopathy secondary to aluminium sulphate toxicity while being treated for bladder irrigation. The man, who had a history of coronary artery disease status post coronary artery bypass graft surgery, bladder cancer status post-radiation cystitis, was admitted for haematuria and continuous bladder irrigation. On the same morning, an aluminum level was 18 µg/L. Encephalopathy secondary to aluminium sulphate toxicity was considered. [Extracted from the article]

A 36-year-old female developed acute iron overload while being treated with ferric carboxymaltose for iron deficiency anaemia; she had been erroneously prescribed with an overdose of ferric carboxymaltose. After 1 month, her anaemia was resolved, however, she had elevated serum ferritin value as 3500 ng/mL. Her liver MRI showed significant decrease in the liver iron accumulation and the skin discolouration was reduced. [Extracted from the article]

In a multicentre study from the Rete Ematologica Lombarda (IRON-M study) involving 45 patients, two patients [ I ages and sexes not stated i ] were described, who developed gastrointestinal symptoms (1 patient) and skin reaction (1 patient) during iron chelation therapy with deferasirox. The patients, who had myelofibrosis with transfusion-dependent anaemia, had been receiving iron chelation therapy with deferasirox [Exjade] dispersible tablets for oral suspension [ I dosages not stated i ] since 2010. Subsequently, one patient developed grade 3 gastrointestinal symptoms and another patient developed grade 1-2 skin reaction [ I durations of treatments to reactions onsets and outcomes not stated i ]. [Extracted from the article]

In a study of 200 children (aged above 3 years), who had thalassaemia and who had undergone otoscopy evaluation between October 2018 and April 2019, a child [ I sex and exact age not stated i ] was described, who developed sensorineural hearing loss (SNHL) during oral chelation drug therapy with deferasirox, deferiprone and deferoxamine. The child, who had thalassaemia and who had been receiving oral chelation therapy with deferasirox, deferiprone and deferoxamine [ I dosages not stated i ], subsequently underwent an otoscopy evaluation. A pure-tone audiometry (PTA) at different frequencies and otoscopy evaluation were performed, results of which were consistent with chelators-induced ototoxicity, manifesting as SNHL [ I durations of treatments to reaction onset not stated; outcome not stated i ]. [Extracted from the article]

The article describes the case of a 15-year-old girl who presented with gastrointestinal bleeding during treatment with trientine for Wilson disease.

The article presents a case study of a 28-year old man who developed fatal septicemia with Vibrio vulnificus while receiving treatment with deferoxamine as an iron chelation therapy.

A case report of a man is presented who developed iron deficiency anaemia when received drug deferasirox and deferoxamine during iron chelation therapy.

The article presents cases where four women having a history of aceruloplasminemia developed agranulocytosis while administered with deferiprone during a chelation therapy session.

An abstract of the article "Clinical and imaging deterioration of a mild case of Wilson's disease after chelation therapy" by C. Kleoniki and others is presented.

An abstract of the article "Pregnancy outcome after chelation therapy in Wilson disease" by K. Dathe and others is presented.

The article describes the case of a 10-year-old girl with Diamond-Blackfan anaemia who developed fatal agranulocytosis after deferiprone was added to her chelation therapy. Information is presented on the patient's clinical symptoms and treatment regimen. Findings of laboratory tests conducted on the patient are discussed.

The article discusses research being done on chelating agents. It references a study by M. J. Brown, T. Willis, B. Omalu and R. Leiker, published in the August 2006 issue of "Pediatrics." The research involves three patients who developed fatal hypocalcemia during chelation therapy. Cardiac arrhythmia due to hypocalcemia associated with edetic acid infusion and vacuolar cardiomyopathy was ruled as the cause of death.

The article presents a case report of several patients who developed lead poisoning following ingestion of Ayurvedic medicines. One woman patient, who had been taking Ayurvedic powders and black tablets to aid her fertility, was presented with vomiting and epigastric pain. She was required chelation therapy. Another man, who had been taking Ayurvedic fertility pills, was presented with a history of right upper quadrant colicky abdominal pain. He received chelation therapy and edetic acid infusions.

An abstract of the article "Treatment of Superficial siderosis with iron chelation therapy," by G. Cummins and colleagues is presented.

The article presents a case study of seven male and three female patients who developed nephrolithiasis while undergoing iron chelation therapy with deferasirox deferiprone for thalassemia major.

The article describes the case of a 26-year-old man who developed Stevens-Johnson syndrome (SJS) following chelation therapy with unithiol after being exposed to lead-containing gas at his workplace.

The article describe two case reports of patients with sickle cell disease who experienced various toxicities during chelation therapy with deferoxamine or deferasirox, published in the October 2010 issue of the "American Journal of Hematology."

The article describes the case of a 32-year-old man who developed fatal multiple organ failure after receiving chelation therapy with deferasirox.

The article describes the case of a 60-year-old man who experienced an exacerbation of chronic kidney disease while receiving a lead-containing ayurvedic herbal product. The patient had a history of hypertension, type 2 diabetes with retinopathy and elevated serum creatinine levels. The herbal product he took was found to contain lead. The medicine was stopped and he received blood chelation therapy with infusion of intravenous sodium calcium edetate.

The article describes the case of a 29-year-old man who experienced a re-activation of hepatitis B virus (HBV) infection while receiving combined treatment with deferiprone and deferoxamine for thalassaemia. It discusses the clinical history of the patient, the results of his physical and laboratory tests, and the management of the infection. Patient outcome showed an improvement in his condition after two years of deferiprone treatment.

The article describes the case of an 11-month-old boy who experienced mercury poisoning symptoms while receiving a Chinese medicine for appetite stimulation. Particular focus is given to the boy's diet and body weight. His other symptoms included poor sleep, malaise, increased salivation, irritability and lack of interest. The results of his physical and laboratory examinations are also provided. His development and condition improved after undergoing chelating therapy and receiving amlodipine.

The article describes the case of the adverse reaction of disodium edetate, a cardiovascular drug. A 5-year-old boy, who underwent chelation therapy for autism, experienced heart arrest during his third intravenous (IV) administration of disodium edetate. The cause of death of the patient was determined as acute cerebral hypoxic-ischaemic injury following diffuse subendocardial necrosis secondary to disodium edetate-induced hypocalcaemia.

The article presents the case of a 24-year-old man who developed lead poisoning while taking Ayurvedic drugs for erectile dysfunction. The patient presented with a history of colicky abdominal pain and had developed obstipation and gaseous distension of his abdomen. The man was given succimer chelation therapy and his autonomic activity continually improved.

The article discusses case reports of three patients, who died due to complications from chelation therapy-related hypocalcaemia.